Healthcare
Recordati Industria Chimica e Farmaceutica S.p.A.(RCDTF)
Live Price
Offline$60.00
+0.00% today
1Y Change
-8.31%
Window
Jun 23, 2025 โ Jun 11, 2026
- Market Cap
- $10.14B
- Revenue Growth
- +11.8%
- EPS Growth
- +6.4%
- Dividend Yield
- 2.6%
Coverage: 250 bars ยท Jun 23, 2025 โ Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) is a Healthcare stock with a market cap of $10.14B and listed on OTC. The stock last traded around $60.00 and down 8.3% across the available one-year price window (Jun 23, 2025 โ Jun 11, 2026). Baseline metrics include revenue growth of +11.8%, EPS growth of +6.4%, a dividend yield of 2.6%. What stands out right now is revenue +11.8%, EPS +6.4%, free cash flow +282.0% with operating margin 27.5% and ROIC 12.1%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 23.0 and price/sales 3.9. Stock Foundry combines RCDTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.8% vs +7.6% peer median
Operating Margin
Above sector median
+27.5% vs +19.4% peer median
P/E
Below sector median
23.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +11.8% and EPS at +6.4%, with operating margin around 27.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | +0.0% | +7.4% |
2026 Mar 31, 2026 | +2.7% | +0.0% | +0.0% | -1.9% |
2025 Nov 11, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RCDTF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RCDTF Max Drawdown
-14.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RCDTF and SPY.
Company Overview
Recordati Industria Chimica e Farmaceutica S.p.A.
Other OTC
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.ร R.L.
- Leadership
- Robert Koremans
- IPO Date
- Dec 17, 2010
- Employees
- 4.6k
- Street Address
- 1, Via Matteo Civitali
- Mailing
- Milan, MI, 20148
- Region
- Milan, MI, IT
- Reporting Currency
- USD
- Investor Line
- 39 02 487871
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.0
- EV/EBITDA
- 13.7
- Price/Sales
- 3.9
- Price/Book
- 5.3
Growth
- Revenue
- +11.8%
- EPS
- +6.4%
- Free Cash Flow
- +282.0%
Profitability
- Gross Margin
- 68.3%
- Operating Margin
- 27.5%
- Net Margin
- 16.9%
- ROE
- 23.1%
- ROIC
- 12.1%
Balance Sheet
- Debt/Equity
- 1.29
- Current Ratio
- 1.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.